RU2018143809A3 - - Google Patents

Download PDF

Info

Publication number
RU2018143809A3
RU2018143809A3 RU2018143809A RU2018143809A RU2018143809A3 RU 2018143809 A3 RU2018143809 A3 RU 2018143809A3 RU 2018143809 A RU2018143809 A RU 2018143809A RU 2018143809 A RU2018143809 A RU 2018143809A RU 2018143809 A3 RU2018143809 A3 RU 2018143809A3
Authority
RU
Russia
Application number
RU2018143809A
Other languages
Russian (ru)
Other versions
RU2763493C2 (ru
RU2018143809A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018143809A publication Critical patent/RU2018143809A/ru
Publication of RU2018143809A3 publication Critical patent/RU2018143809A3/ru
Application granted granted Critical
Publication of RU2763493C2 publication Critical patent/RU2763493C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2018143809A 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна RU2763493C2 (ru)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US62/335,599 2016-05-12
US62/335,611 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414606P 2016-10-28 2016-10-28
US201662414599P 2016-10-28 2016-10-28
US62/414,606 2016-10-28
US62/414,599 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (3)

Publication Number Publication Date
RU2018143809A RU2018143809A (ru) 2020-06-15
RU2018143809A3 true RU2018143809A3 (enExample) 2020-09-17
RU2763493C2 RU2763493C2 (ru) 2021-12-29

Family

ID=58745465

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018143809A RU2763493C2 (ru) 2016-05-12 2017-05-11 Способы лечения расстройств циркадного ритма сна

Country Status (16)

Country Link
US (2) US11096941B2 (enExample)
EP (2) EP3454859B1 (enExample)
JP (2) JP6888026B2 (enExample)
KR (2) KR20230043227A (enExample)
CN (1) CN109640998A (enExample)
AU (3) AU2017264871B2 (enExample)
CA (1) CA3022068A1 (enExample)
ES (1) ES2904625T3 (enExample)
IL (2) IL291791B2 (enExample)
MX (1) MX379318B (enExample)
MY (1) MY199382A (enExample)
RU (1) RU2763493C2 (enExample)
SG (1) SG11201809527UA (enExample)
TW (1) TWI795359B (enExample)
WO (1) WO2017197160A1 (enExample)
ZA (1) ZA201807903B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291791B2 (en) * 2016-05-12 2025-09-01 Eisai R&D Man Co Ltd Methods for treating sleep timing disorders
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
US20220305012A1 (en) * 2019-06-26 2022-09-29 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
EP4073058A1 (en) * 2019-12-11 2022-10-19 Teva Czech Industries s.r.o. Solid state form of lemborexant
TW202140014A (zh) * 2020-01-16 2021-11-01 日商衛材R&D企管股份有限公司 萊博雷生的原料藥及含有其的醫藥組成物
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
US20250064802A1 (en) * 2021-07-26 2025-02-27 Eisai R&D Management Co., Ltd. Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
WO2024064897A1 (en) 2022-09-23 2024-03-28 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases
JPWO2025033432A1 (enExample) 2023-08-08 2025-02-13

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
SI2626350T1 (sl) 2010-09-22 2015-09-30 Eisai R&D Management Co., Ltd. Spojina ciklopropana
WO2013119639A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
SG10202007759RA (en) * 2014-10-23 2020-09-29 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
IL291791B2 (en) 2016-05-12 2025-09-01 Eisai R&D Man Co Ltd Methods for treating sleep timing disorders

Also Published As

Publication number Publication date
IL291791B1 (en) 2025-05-01
IL291791B2 (en) 2025-09-01
EP3454859A1 (en) 2019-03-20
RU2763493C2 (ru) 2021-12-29
MY199382A (en) 2023-10-25
AU2025205336A1 (en) 2025-07-31
EP4056180A1 (en) 2022-09-14
AU2023203418A1 (en) 2023-06-29
JP2019518732A (ja) 2019-07-04
ZA201807903B (en) 2021-04-28
US11096941B2 (en) 2021-08-24
MX379318B (es) 2025-03-10
KR20190013820A (ko) 2019-02-11
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
IL291791A (en) 2022-06-01
US20210353625A1 (en) 2021-11-18
JP2021120410A (ja) 2021-08-19
AU2017264871B2 (en) 2023-03-16
CN109640998A (zh) 2019-04-16
NZ748555A (en) 2025-06-27
IL262803A (en) 2018-12-31
ES2904625T3 (es) 2022-04-05
MX2018013663A (es) 2019-07-18
RU2018143809A (ru) 2020-06-15
TWI795359B (zh) 2023-03-11
JP7150096B2 (ja) 2022-10-07
JP6888026B2 (ja) 2021-06-16
EP3454859B1 (en) 2021-12-01
WO2017197160A1 (en) 2017-11-16
US20200179382A1 (en) 2020-06-11
AU2017264871A1 (en) 2018-11-15
KR102511855B1 (ko) 2023-03-20
BR112018073037A2 (pt) 2019-02-26
IL262803B (en) 2022-05-01
CA3022068A1 (en) 2017-11-16
SG11201809527UA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
BR112019002665A2 (enExample)
BR112018004986A2 (enExample)
BR112019008105A2 (enExample)
BR112019001429A2 (enExample)
BR212018070320U2 (enExample)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019000061B1 (pt) Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR112018072681B1 (pt) Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019006736A2 (enExample)
BR112019003108A2 (enExample)
BR102016018018A2 (enExample)
BE2016C016I2 (enExample)
CN303537333S (enExample)
CN303536494S (enExample)
CN303538222S (enExample)
CN303629307S (enExample)
CN303536111S (enExample)
CN303537291S (enExample)
CN303536207S (enExample)
CN303536593S (enExample)